Feds target joint docs in kickbacks probe

Share this article:
Federal investigators are zeroing in on individual hip and knee surgeons in an investigation into kickbacks to doctors by orthopedic device manufacturers, The New York Times reports.

US attorney for the district of New Jersey Christopher Christie recently addressed the sales meetings of five companies, the Times said, quoting a Stryker executive as saying Christie told them “I've dealt with the supply issue, now I need to deal with the demand issue.”

Four companies – Biomet, Johnson & Johnson's DePuy Orthopaedics, Smith & Nephew and Zimmer Holdings – agreed to pay a combined total of $310 million to settle civil charges related to the inquest in September. Stryker was included in that settlement but did not pay a fine, as it was the first to cooperate in the investigation. All entered corporate integrity agreements.

The firms were accused of paying kickbacks to doctors in the form of consulting fees in exchange for recommending their products to patients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...